SEOM-GEICO clinical guidelines on endometrial cancer (2021).

Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse....

Descripción completa

Detalles Bibliográficos
Autores: Barretina-Ginesta, Maria Pilar, Quindos, Maria, Alarcon, Jesus Damian, Esteban, Carmen, Gaba, Lydia, Gomez, Cesar, Fidalgo, Jose Alejandro Perez, Romero, Ignacio, Santaballa, Ana, Rubio-Perez, Maria Jesus
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16456
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/16456
Access Level:acceso abierto
Palabra clave:Diagnosis
Endometrial cancer
Guideline
Treatment
id ES_68e0c6e1eeb608dc4c60acbfaa331cd2
oai_identifier_str oai:incliva.fundanetsuite.com:p16456
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM-GEICO clinical guidelines on endometrial cancer (2021).Barretina-Ginesta, Maria PilarQuindos, MariaAlarcon, Jesus DamianEsteban, CarmenGaba, LydiaGomez, CesarFidalgo, Jose Alejandro PerezRomero, IgnacioSantaballa, AnaRubio-Perez, Maria JesusDiagnosisEndometrial cancerGuidelineTreatmentEndometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.SPRINGER INT PUBL AG2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16456Clinical & Translational OncologyISSN: 1699048XISSNe: 16993055reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p164562026-06-07T16:35:31Z
dc.title.none.fl_str_mv SEOM-GEICO clinical guidelines on endometrial cancer (2021).
title SEOM-GEICO clinical guidelines on endometrial cancer (2021).
spellingShingle SEOM-GEICO clinical guidelines on endometrial cancer (2021).
Barretina-Ginesta, Maria Pilar
Diagnosis
Endometrial cancer
Guideline
Treatment
title_short SEOM-GEICO clinical guidelines on endometrial cancer (2021).
title_full SEOM-GEICO clinical guidelines on endometrial cancer (2021).
title_fullStr SEOM-GEICO clinical guidelines on endometrial cancer (2021).
title_full_unstemmed SEOM-GEICO clinical guidelines on endometrial cancer (2021).
title_sort SEOM-GEICO clinical guidelines on endometrial cancer (2021).
dc.creator.none.fl_str_mv Barretina-Ginesta, Maria Pilar
Quindos, Maria
Alarcon, Jesus Damian
Esteban, Carmen
Gaba, Lydia
Gomez, Cesar
Fidalgo, Jose Alejandro Perez
Romero, Ignacio
Santaballa, Ana
Rubio-Perez, Maria Jesus
author Barretina-Ginesta, Maria Pilar
author_facet Barretina-Ginesta, Maria Pilar
Quindos, Maria
Alarcon, Jesus Damian
Esteban, Carmen
Gaba, Lydia
Gomez, Cesar
Fidalgo, Jose Alejandro Perez
Romero, Ignacio
Santaballa, Ana
Rubio-Perez, Maria Jesus
author_role author
author2 Quindos, Maria
Alarcon, Jesus Damian
Esteban, Carmen
Gaba, Lydia
Gomez, Cesar
Fidalgo, Jose Alejandro Perez
Romero, Ignacio
Santaballa, Ana
Rubio-Perez, Maria Jesus
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Diagnosis
Endometrial cancer
Guideline
Treatment
topic Diagnosis
Endometrial cancer
Guideline
Treatment
description Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16456
url https://incliva.portalinvestigacion.com/publicaciones/16456
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER INT PUBL AG
publisher.none.fl_str_mv SPRINGER INT PUBL AG
dc.source.none.fl_str_mv Clinical & Translational Oncology
ISSN: 1699048X
ISSNe: 16993055
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409991555809281
score 15,811543

Similares en LA Referencia